Related Experiment Video

Updated: Jun 18, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Pegfilgrastim in children with severe congenital neutropenia

Francesca Fioredda1, Michaela Calvillo, Marina Lanciotti

  • 1Haematology Unit, Giannina Gaslini Childrens' Hospital, Genoa, Italy. francescafioredda@ospedale-gaslini.ge.it

Pediatric Blood & Cancer
|November 21, 2009
PubMed

Insights

Pegfilgrastim treatment in severe congenital neutropenia (SCN) led to increased neutrophil counts and reduced infections in pediatric patients. This suggests pegfilgrastim is a viable option for SCN, offering similar G-CSF exposure to filgrastim.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Severe congenital neutropenia (SCN) is a rare condition characterized by extremely low neutrophil counts, increasing susceptibility to infections.
  • Current treatments often involve granulocyte colony-stimulating factor (G-CSF) to boost neutrophil production.
  • Pegfilgrastim, a long-acting G-CSF analog, offers a potentially more convenient dosing schedule.

Observation:

  • A pilot study investigated the use of pegfilgrastim in two pediatric patients with SCN.
  • Patients received pegfilgrastim at a dose of 100 mcg/L/dose every 9-12 days.
  • Serum G-CSF concentrations were monitored and compared to those seen with filgrastim.

Findings:

  • Both pediatric patients demonstrated a significant increase in their absolute neutrophil count (ANC).
  • Infectious load was reduced, indicating improved immune function.
  • Patients reported an enhanced quality of life.
  • Observed serum G-CSF concentrations with pegfilgrastim were comparable to those achieved with filgrastim.

Implications:

  • Pegfilgrastim shows promise as an effective treatment for severe congenital neutropenia in pediatric populations.
  • The similar G-CSF exposure profile suggests pegfilgrastim can achieve therapeutic effects comparable to traditional filgrastim.
  • Further research into pegfilgrastim's long-term efficacy and safety in SCN is warranted.

More Related Videos

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...